| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8450299 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
Oct, 2025
(1 year, 5 months from now) | |
| US8415332 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
Mar, 2029
(4 years from now) | |
Quartette is owned by Teva Branded Pharm.
Quartette contains Ethinyl Estradiol; Levonorgestrel.
Quartette has a total of 2 drug patents out of which 0 drug patents have expired.
Quartette was authorised for market use on 28 March, 2013.
Quartette is available in tablet;oral dosage forms.
Quartette can be used as prevention of pregnancy.
The generics of Quartette are possible to be released after 11 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2016 |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 28 March, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
How can I launch a generic of QUARTETTE before it's drug patent expiration?
More Information on Dosage
QUARTETTE family patents
